November 27, 2021

Moderna is not recommended at this stage for the third dose in France

In a press release on Friday, the High Authority for Health (HAS) recommends using exclusively Pfizer vaccine and BioNtech, and to wait for an opinion from the European Medicines Agency before possibly using the Moderna vaccine for booster injection against Covid-19.

Article written by

Posted

Update

Reading time : 1 min.

The vaccine from Pfizer and BioNTech preferred for the administration of a third dose of vaccine against Covid-19. In a press release, Friday, October 15, the High Authority for Health (HAS) recommends using exclusively the vaccine from Pfizer and BioNtech, and to wait for an opinion from the European Medicines Agency before possibly using the Moderna vaccine for booster injection against Covid-19.

At this stage, the recall campaign in France concerns those over 65, the immunocompromised and their relatives, people at risk, such as patients suffering from obesity or diabetes, as well as caregivers. In each case, you must have been vaccinated for at least six months.

In its last opinion of October 6, the High Authority for Health recommended for this recall the use of the Pfizer vaccine, without ruling out the use of Moderna, which has not yet obtained marketing authorization (AMM). for the reminder. “The announcements from various health authorities have highlighted the unknowns that remain about the dose and the target population for the Spikevax® recall. (Modern) and justify waiting for the European body to provide the details expected within the framework of the MA under examination “, now writes the HAS.

In early October, the Scandinavian countries suspended vaccination via Moderna for the youngest or even, in Iceland, for all adults. They announced that they would inform the European Medicines Agency of studies suggesting a possible increased risk of myocarditis and pericarditis linked to this vaccine. “These remain rare and spontaneously resolve in almost all cases”, underlines the HAS.

“But this context, the currently moderate circulation of the virus and the work in progress at the European Medicines Agency to define the target population (what age limit) and above all the dosage (full or half-dose), are driving the HAS to return more strictly to a position of caution “, justifies the High Authority of health.